Roaj Ujjin, MD
Internal Medicine · Marietta, GANPI 1811987126
Payments from drug & device makers
Across 112 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$376
- Novo Nordisk$271
- Pfizer$226
- Abbott$140
- GSK$131
- Dexcom, Inc.$105
- plus $823 from 22 others
What the payments were for
- Food & beverage$2,03098%
- Education$422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 19 | $376 |
| Novo Nordisk | 17 | $271 |
| Pfizer | 11 | $226 |
| Abbott | 7 | $140 |
| GSK | 7 | $131 |
| Dexcom, Inc. | 4 | $105 |
| AbbVie(2 entities) | 6 | $99 |
| Lilly USA, LLC | 5 | $90 |
| Merck | 5 | $72 |
| AstraZeneca | 5 | $68 |
| Exact Sciences | 4 | $63 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Johnson & Johnson | 3 | $52 |
| Astellas Pharma US Inc | 2 | $51 |
| Boston Scientific | 1 | $34 |
| Shield Therapeutics Inc | 1 | $26 |
| Dynavax Technologies Corporation | 1 | $25 |
| Novartis | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Lifescan, Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Sanofi | 1 | $16 |
| Eisai Inc. | 1 | $13 |
| Gilead | 1 | $13 |
How this compares
$2,072 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $117,480 |
| EliquisApixaban | 60 | $53,405 |
| JardianceEmpagliflozin | 50 | $46,158 |
| JanuviaSitagliptin Phosphate | 35 | $25,856 |
| FarxigaDapagliflozin Propanediol | 39 | $20,410 |
| Xtampza ErOxycodone Myristate | 11 | $15,867 |
| MounjaroTirzepatide | 11 | $12,244 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $4,665 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $4,328 |
| Glipizide-MetforminGlipizide/Metformin Hcl | 59 | $3,826 |
| Atorvastatin Calcium | 428 | $3,458 |
| ValacyclovirValacyclovir Hcl | 24 | $3,088 |
| Fluticasone Propionate | 59 | $2,702 |
| Ezetimibe | 113 | $2,622 |
| Levothyroxine Sodium | 303 | $2,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $271 | $117,480120 claims |
| PfizerEliquis, Paxlovid | $226 | $54,77376 claims |
| Boehringer IngelheimJardiance | $19 | $46,15850 claims |
| MerckJanuvia | $72 | $25,85635 claims |
| AstraZenecaFarxiga | $68 | $20,41039 claims |
| Lilly USA, LLCMounjaro | $90 | $12,24411 claims |
| AbbVieSynthroid | $99 | $97923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Marietta
- Ebon BourneMarietta$242K
- Ramprasad SubramaniamMarietta$142K
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.